Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin

NCT01632163 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

447

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Lixisenatide (AVE0010)
DRUG: Placebo

Sponsor

Sanofi